This activity is expired and is no longer available for CME credit.


Advancing Science: Incorporating New Options in Systemic Juvenile Idiopathic Arthritis Treatment

Author(s)/Faculty: Fabrizio De Benedetti, MD, PhD
Release Date: 6/12/2014Expiration Date: 6/11/2015
Credit Type: CME / ParticipationNumber of Credits: 0
Content Type: MultimediaProvider:
Systemic juvenile idiopathic arthritis (JIA) accounts for 5% to 15% of patients diagnosed with JIA and is the most severe form of the disease. Systemic JIA is responsible for a disproportionate share of the morbidity and mortality associated with childhood arthritis. In the past 2 years, data regarding the treatment of systemic JIA have increased rapidly, and the first 2 drugs have been approved by the FDA for treatment of this disease. In addition, new recommendations for the treatment of systemic JIA have recently been released by the American College of Rheumatology. Pediatric rheumatologists and other health care professionals involved in the treatment of patients with JIA must be knowledgeable about the guidelines, recent data and appropriate use of new agents in order to improve patient outcomes. Although better treatment options are now available, 2 severe complications of systemic JIA, macrophage activation syndrome and pulmonary hypertension, have not decreased. Thus, this educational activity will focus on management of systemic JIA and early intervention strategies for these potentially lethal complications.